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ABstrAct
Objectives Skin fibrosis mediated by activated 
dermal fibroblasts is a hallmark of systemic sclerosis 
(SSc), especially in the subset of patients with diffuse 
disease. transforming growth factor-beta (tGFβ) and 
interleukin-6 (IL-6) are key candidate mediators in SSc. 
our aim was to elucidate the specific effect of IL-6 
pathway blockade on the biology of SSc fibroblasts 
in vivo by using samples from a unique clinical 
experiment—the faSScinate study—in which patients 
with SSc were treated for 24 weeks with tocilizumab 
(tCZ), an IL-6 receptor-α inhibitor.
Methods We analysed the molecular, functional and 
genomic characteristics of explant fibroblasts cultured 
from matched skin biopsy samples collected at baseline 
and at week 24 from 12 patients receiving placebo (n=6) 
or tCZ (n=6) and compared these with matched healthy 
control fibroblast strains.
results the hallmark functional and molecular-
activated phenotype was defined in SSc samples and 
was stable over 24 weeks in placebo-treated cases. rnA 
sequencing analysis robustly defined key dysregulated 
pathways likely to drive SSc fibroblast activation in vivo. 
treatment with tCZ for 24 weeks profoundly altered the 
biological characteristics of explant dermal fibroblasts 
by normalising functional properties and reversing gene 
expression profiles dominated by tGFβ-regulated genes 
and molecular pathways.
conclusions We demonstrated the exceptional 
value of using explant dermal fibroblast cultures from 
a well-designed trial in SSc to provide a molecular 
framework linking IL-6 to key profibrotic pathways. the 
profound impact of IL-6r blockade on the activated 
fibroblast phenotype highlights the potential of IL-6 as a 
therapeutic target in SSc and other fibrotic diseases.
trial registration number nCt01532869; post-
results.
IntrOductIOn
Systemic sclerosis (SSc) is characterised by fibrosis 
of the skin and internal organs, autoimmunity and 
vasculopathy.1 Although the biological mechanisms 
underlying SSc are not fully understood, interplay 
between vasculopathy, autoimmunity and fibrosis 
may perpetuate a state of aberrant wound repair.2 
Disease modification remains elusive, and treatment 
focuses on complications such as interstitial lung 
disease, pulmonary artery hypertension and periph-
eral vasculopathy.3 Clinical heterogeneity is a hall-
mark of SSc, and patients with severe progressive 
diffuse skin involvement have poor outcomes; more 
effective treatment for this subset of patients is an 
important unmet medical need.4 
Fibroblasts play a central role in the biology 
of the disease5 by interacting with endothelial 
cells6 and leucocytes7 in a complex biological 
network involving cytokines and adhesion mole-
cules,8 resulting in excess deposition of extra-
cellular matrix proteins and in tissue stiffening. 
Transforming growth factor-beta (TGFβ) plays a 
central role in fibrosis9 by promoting the differ-
entiation of fibroblasts into myofibroblasts and 
by inducing profibrotic molecules and prolifera-
tion.10 Interleukin-6 (IL-6) also plays an important 
role in SSc11 by regulating the function of immune 
and non-immune cells. Dermal fibroblasts from 
patients with SSc express increased levels of IL-612; 
elevated levels of IL-6 are associated with early 
disease,13 and increased serum IL-6 level predicts 
higher mortality risk, worse skin involvement and 
increased pulmonary decline.14 15 IL-6 is known to 
induce TGFβ production by cardiac fibroblasts16 
and to enhance TGFβ-signalling in dermal fibro-
blasts17 and cardiac fibroblasts.18 Conversely, TGFβ 
regulates the expression of IL-6 by lung fibroblasts19 
and airway smooth muscle cells.20
To elucidate the specific effect of IL-6 on the 
biology of fibroblasts in vivo, we took advantage 
of a unique clinical experiment—the faSScinate 
study—in which SSc patients were treated for 24 
weeks with tocilizumab (TCZ), an IL-6 recep-
tor-α blocking antibody. The faSScinate study was 
a randomised, double-blind, placebo (PBO)-con-
trolled phase 2 study of TCZ in adult SSc patients 
with <5 years’ disease duration, a modified Rodnan 
skin score (mRSS) between 15 and 40 units and 
active progressive disease according to specified 
clinical or laboratory features. No concomitant 
immunosuppressive medication was permitted 
at study entry or during the first 24 weeks of the 
trial.21 In this study, 43 patients with SSc received 
weekly TCZ 162 mg subcutaneously and 44 
patients with SSc received weekly PBO subcutane-
ously. As previously reported, primary clinical data 
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from the faSScinate trial showed a trend of benefit in favour of 
TCZ for the primary endpoint or mRSS and a strong trend at 48 
weeks together with congruent benefit in exploratory endpoints 
including lung function. Based on these results, a phase 3 trial of 
TCZ is under way ( ClinicalTrials. gov, NCT02453256).
Here we define the molecular and functional phenotype 
of explant dermal fibroblasts from a representative subset of 
patients with SSc enrolled into faSScinate and demonstrate a 
profound reversal of the hallmark profibrotic properties of these 
cells after treatment with TCZ for 24 weeks compared with 
controls from the PBO arm of the trial.
MetHOds
sample collection and analysis
Culture of dermal explant fibroblasts from patients with 
SSc enrolled in the faSScinate study ( ClinicalTrials. gov, 
NCT01532869) and matched controls was performed as 
described, as was protein quantification using Western blot 
analysis.15 Cell migration was assessed using scratch wound 
assay,22 and contractility assays were performed on 3D collagen 
gel lattices.23 Gene expression patterns were analysed using Inge-
nuity Pathway Analysis (IPA; Qiagen). Additional methodology 
is described in online supplementary appendix S1.
statistical analysis
For functional assays, means were compared using Tukey’s 
multiple comparison test. Correlations were calculated using the 
Spearman ρ. The Benjamini and Hochberg False Discovery Rate 
method was used to correct for multiple comparisons. All statis-
tical calculations were conducted in JMP V.11.1 (SAS Institute).
results
ssc explant dermal fibroblasts present hallmark functional 
properties of activated fibrotic cells
Dermal fibroblasts were cultured from fresh skin biopsy 
samples collected at baseline and at week 24 from consecutive 
PBO-treated and TCZ-treated patients enrolled in the faSS-
cinate study (online supplementary table S1).21 Confirming 
earlier reports,22 dermal fibroblasts isolated from patients with 
SSc at baseline produced significantly higher levels of connec-
tive tissue growth factor (CTGF), collagen alpha 1 (Col1) and 
alpha-smooth muscle actin (αSMA) than normal fibroblasts 
(NFs) (NF vs SSc; p<0.0001 for all three factors) (figure 1A–C). 
Migratory capacity and contractility activity were also enhanced 
compared with NF (NF vs PBO baseline and NF vs TCZ base-
line, p<0.0001 for both) (figure 1D,E). These results indicate 
that the SSc explant dermal fibroblasts obtained in this study 
have the hallmark functional characteristics of activated fibrotic 
fibroblasts.
ssc dermal fibroblasts collected at baseline: typical 
profibrotic signature dominated by genes regulated by tGFβ
Using RNA sequencing (RNA-Seq), we compared the expression 
profiles of SSc fibroblasts collected at baseline (SSc) with those 
of NF. Figure 2 depicts the expression values of NF and SSc base-
line fibroblasts for 578 protein-coding genes significantly differ-
entially expressed (criteria: fold difference ≥1.5; median reads 
per kilobase of transcript per million mapped reads ≥1, adjusted 
p≤0.05). Of the 578 selected genes, 145 are known to be regu-
lated by TGFβ in human dermal or lung fibroblasts,20 24–26 indi-
cating that this pathway is dominant in these cells (figure 2). 
Of note, baseline erythrocyte sedimentation rate (ESR) and C 
reactive protein and IL-6 levels were not associated with distinct 
baseline gene expression profiles (online supplementary table 
S2).
tcZ treatment for 24 weeks attenuates the functional 
properties of ssc explant fibroblasts
Comparison of functional measures between fibroblasts 
collected at baseline and week 24 from patients treated with 
TCZ showed a significant decrease in protein production, in 
migration (increase in gap size) and in contractility (increase in 
gel weight) (figure 3), indicating that therapeutic treatment with 
TCZ results in a significant attenuation of the hallmark func-
tional properties of SSc fibroblasts. In contrast, the phenotype of 
SSc fibroblasts was stable in PBO-treated patients.
Profibrotic expression profile of ssc dermal fibroblasts: 
normalised in tcZ-treated patients and stable in PBO-treated 
patients
Figure 4 depicts expression levels for the PBO and TCZ groups 
at week 24 compared with the matching sample at baseline. 
In the PBO-treated group (figure 4), no significant difference 
was detected (see also online supplementary figure S1), indi-
cating that baseline expression profile is sustained over ≥24 
weeks in the absence of immunosuppressants. In contrast, in the 
TCZ group (figure 4), we identified 2136 significantly differ-
entially expressed genes; of those, 411 were also differentially 
expressed in the SSc/NF comparison. Remarkably, the expression 
pattern of the 411 shared genes in the TCZ group was opposite 
to that observed in the SSc versus NF comparison (figure 4). 
Of note, 167 and 1725 genes were significantly differentially 
expressed in SSc/NF and TCZ week 24/baseline comparisons, 
respectively. For most genes, differential expression trends were 
similar to those observed in the 411 shared genes (online supple-
mentary figure S2). Thus, gene expression data confirm that 
therapeutic treatment with TCZ for 24 weeks profoundly alters 
the SSc-associated molecular phenotype of explanted dermal 
fibroblasts. Considering this striking biological effect of TCZ, 
we explored the correlation between gene expression and mRSS 
across all patients and time points. Of the 411 genes analysed, 35 
had a nominal correlation p≤0.05 (online supplementary table 
S3), and only one, PRKCρ, remained significant after correction 
for multiple testing. Treatment with TCZ resulted in a significant 
upregulation of PRKCρ expression that was underexpressed in 
SSc dermal fibroblasts at baseline, as previously reported in SSc 
lung fibroblasts.27
treatment with tcZ for 24 weeks: reversal of activation 
status of key pathological pathways associated with ssc
We used the IPA (Qiagen) to assign biological functions to 
networks of all significantly differentially expressed genes (2303 
genes) from the SSc versus NF and the TCZ week 24 versus 
baseline comparisons (online supplementary figure S1). Of the 
609 significantly enriched pathways, we selected the top 50 
pathways with the highest combined absolute Z scores (figure 5) 
and grouped them into 10 major biological nodes; annotations 
for the selected pathways are provided in (online supplemen-
tary table S4). Most pathways defined by genes that were only 
differentially expressed in one comparison overlapped with the 
50 pathways.
The fibrosis node is dominated by TGFβ-related pathways but 
also includes a pathway related to the activity of lysophosphatidic 
acid and to the antifibrotic transcription factor KLF2. The contrac-
tion node regroups 11 pathways related to cellular contractility 
machinery. The migration node includes four pathways positively 
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related to cell movement. The growth node contains three path-
ways positively related to proliferation and cell survival. The 
five pathways grouped under the cardiovascular node are gener-
ally associated with endothelial and vascular smooth muscle cell 
biology but are also known to be positively related to fibrosis. 
Although the main function of the two pathways grouped under 
the coagulation node is blood clotting, these pathways play an 
important role in linking vascular events to fibrotic events in 
SSc. The activation node regroups eight pathways representing 
major signalling molecules and transcription factors positively 
Figure 1 Explant dermal fibroblasts present hallmark functional properties of activated fibrotic fibroblasts. Production of Col1 (A), CTGF (B) and 
αSMA (C); migration activity (D); and contractility (E) by normal and SSc dermal fibroblasts collected at baseline were analysed by western blot 
densitometry of cell lysates (A–C), scratch assay: percentage of remaining gap size (D) and 3D gel contraction assay: weight of the lattice plug (E), 
respectively. Representative western blot images are presented for each protein analysed (A–C, lower panel); western blot of the reference protein 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown for the corresponding samples. Representative images of scratch assay performed over 
an incubation period of 48 hours are shown (D, lower panel). Representative images of gel contraction assay performed over an incubation period 
of 24 hours are shown (E, lower panel). BL, baseline; Col1, collagen alpha 1; CTGF, connective tissue growth factor; NFs, normal fibroblasts; αSMA, 
alpha-smooth muscle actin; SSc, systemic sclerosis.
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associated with cellular activation. The two pathways grouped in 
the hormones node are thought to contribute to the pathobiology 
of SSc, but the exact mechanisms by which this occurs remain ill 
defined. The inflammation node includes two pathways related to 
the innate immune system. Three of the four pathways included 
in the morphogenesis node belong to the bone morphogenetic 
protein family, and the fourth pathway in this node is related to 
neuregulin biology. Overall, for the baseline SSc explant dermal 
fibroblasts (SSc vs NF comparison), the functions and activation 
status of the top 50 selected pathways depict a highly activated 
Figure 2 Genes differentially expressed by SSc dermal fibroblasts collected at baseline compared with normal dermal fibroblasts represent a typical 
profibrotic signature dominated by genes regulated by TGFβ. Gene expression of normal, SSc PBO and SSc TCZ dermal fibroblasts collected at baseline 
and normalised to the average NF expression. Protein coding RNA showing a median RPKM ≥1, 1.5-fold overexpressed or underexpressed compared 
with NF, with an adjusted p≤0.05, was selected as significantly differentially expressed (n=578). Genes and samples were clustered using the Ward 
method. BL, baseline; NFs, normal fibroblasts; PBO, placebo; RPKM, reads per kilobase of transcript per million mapped reads; SSc, systemic sclerosis; 
TCZ, tocilizumab; TGFβ, transforming growth factor beta.
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fibrotic, motile and contractile phenotype dominated by TGFβ 
superfamily member-regulated biology, where positive regulators 
(n=47) are activated and negative regulators (n=3) are predicted 
to be inhibited. In contrast, for the dermal fibroblasts collected 
from patients treated with TCZ for 24 weeks (TCZ week 24 vs 
baseline comparison), the same 50 pathways are predicted to 
have the opposite activation status. Notably, the level of inhibi-
tion observed with TCZ generally matches the levels of activation 
observed at baseline. Thus, in keeping with the functional assay and 
the gene expression data, the pathway analysis results indicate that 
the 24-week treatment of patients with TCZ almost completely 
reverses the SSc-associated fibrotic phenotype of explant dermal 
fibroblasts.
dIscussIOn
This study provides exceptional insight into the molecular 
pathology of dermal fibroblasts in severe SSc and unique insight 
into the likely key pathways and mediators involved in SSc 
pathogenesis, building on the original observations of LeRoy.28 
By linking the ex vivo data to promising clinical responses in a 
PBO-controlled trial of TCZ, our results also elucidate new and 
Figure 3 Hallmark functional properties of SSc explant dermal fibroblasts are attenuated after treatment of patients with TCZ for 24 weeks. 
Comparison of functional properties of explant dermal fibroblasts from PBO-treated and TCZ-treated patients collected at baseline (week 0) and at 
week 24. Production of Col1 (A), CTGF (B) and αSMA (C); migration activity (E); and contractility (G) were analysed by western blot densitometry 
of cell lysates (A–C), scratch assay: percentage of remaining gap size (E) and 3D gel contraction assay: weight of the lattice plug (G), respectively. 
Representative western blot images are presented for each protein analysed (D, lower panel). Western blot of the reference protein GAPDH is shown 
for the corresponding samples. Representative images of scratch assay performed over an incubation period of 48 hours are shown (F). Representative 
images of gel contraction assay performed over an incubation period of 24 hours are shown (H). For each graph, the average measure of NFs is 
depicted as a dotted line. BL, baseline; Col1, collagen alpha 1; CTGF, connective tissue growth factor; NFs, normal fibroblasts; PBO, placebo; αSMA, 
alpha-smooth muscle actin; SSc, systemic sclerosis; TCZ, tocilizumab.
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important mechanisms by which TCZ may exert an antifibrotic 
effect and build on data from whole-skin gene expression analysis 
from the faSScinate phase 2 study.21 Although it was demonstrated 
that treatment with TCZ for 24 weeks resulted in a specific down-
regulation of genes associated with M2 macrophages and with 
the IL-6 pathway, little specific effect of TCZ treatment could be 
Figure 4 The profibrotic expression profile of SSc dermal fibroblasts tends to be normalised by 24-week treatment of patients with TCZ and tends 
to be stable in PBO-treated patients. Gene expression levels of SSc PBO and SSc TCZ dermal fibroblasts were measured at week 24 and normalised 
to matching baseline expression levels. Protein coding RNA showing a median RPKM ≥1, 1.5-fold overexpressed or underexpressed at week 24 
compared with baseline with an adjusted p≤0.05 was marked as significantly differentially expressed (n=2136). For clarity, only the subset of 411 
genes differentially expressed in both SSc versus NF and in TCZ week 24 versus baseline is shown. Genes and samples were clustered using the 
Ward method. The first column represents the average differential expression of SSc baseline samples compared with NF samples. AVG, average; 
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detected on genes associated with fibrosis at the whole-skin biopsy 
level. Considering the multicellular complexity and relative hetero-
geneity of whole-skin biopsy samples used in this study, we hypoth-
esised that the effect of TCZ on fibroblasts might be masked by 
the gene expression of other cellular compartments. The clinical 
homogeneity of the faSScinate patients and the access to samples 
collected from the same patients before and after 24 weeks of 
treatment with TCZ or PBO allowed us to use relatively small 
numbers of samples to generate robust and reliable results. As a 
result, we are able to confirm and expand on the description of the 
profibrotic properties of SSc dermal fibroblasts at the functional 
and genomic levels, establish that the profibrotic phenotype of SSc 
dermal fibroblasts is stable over ≥24 weeks in patients treated with 
PBO in the absence of immunosuppressant (cyclophosphamide, 
mycophenolate mofetil or methotrexate) and demonstrate that 
treatment of SSc patients with TCZ for 24 weeks profoundly alters 
the biological characteristics of dermal fibroblasts.
The baseline functional and genomic properties of the dermal 
explant fibroblasts analysed in this study closely match those 
described in previous publications.23 24 29 Specifically, the baseline 
Figure 5 Treatment with TCZ for 24 weeks normalises the activation status of molecular and functional pathways associated with the biology of 
SSc fibroblasts. Activation status Z scores for the top 50 associated pathways grouped according to functional nodes. Genes significantly differentially 
expressed in the SSc versus NF (hatched bars) and the TCZ W24 versus baseline (solid black bars) comparisons (online supplementary figure S1) were 
analysed with IPA (Qiagen). Differential gene expression data for all differentially expressed genes are available in online supplementary appendix S2. 
BL, baseline; EGF, epidermal growth factor; IPA, Ingenuity Pathway Analysis; MAPK1, mitogen-activated protein kinase 1; NF, normal fibroblast; SSc, 
systemic sclerosis; TCZ, tocilizumab; TGFβ1, tumour necrosis factor beta 1; VEGFA, vascular endothelial growth factor A; W24, week 24.
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SSc dermal fibroblasts produced elevated levels of profibrotic 
proteins and of migration and contractility activities and differ-
entially expressed a distinct set of fibrosis-related genes with a 
high prevalence of TGFβ-regulated genes. Considering that the 
faSScinate patients were experiencing active progressive disease 
at study entry,21 our observation is consistent with the work of 
Sargent et al,24 who reported that the differential expression of 
genes regulated by TGFβ is associated with more severe disease 
when detected at the whole-biopsy level. Over the years, the 
study of explant dermal fibroblasts in vitro has provided valu-
able insight into the pathobiology of SSc.6 7 22 28 30 31 The fact that 
the phenotypic abnormalities of SSc dermal fibroblasts persist in 
vitro over multiple passages has been critical to this line of inves-
tigation. However, it is important to note that dermal fibroblasts 
are heterogeneous and that they manifest different properties as 
a function of their microenvironment.32 The potential selection 
pressure imposed by isolation, plating and passage procedures 
makes it likely that only a subset of fibroblasts is accessible to 
in vitro studies. These may represent fibroblasts that are more 
motile, better able to acclimate to the culture conditions or have 
higher growth potential, thus perhaps representing stem cell 
population(s). For any of these reasons, we might have selected a 
fibroblast subpopulation in the explant culture conditions more 
sensitive to the effects of IL-6 inhibition.
We used IPA (Qiagen) to associate gene expression with biolog-
ical pathways, focusing on the molecular and cellular biology of 
relevance to fibroblasts. The top 50 pathways associated with 
SSc differentially expressed genes could be grouped into 10 
core biological nodes that covered two levels of biology: biology 
intrinsic to fibroblasts (fibrosis, contraction, migration, growth 
and activation) and biology extrinsic to fibroblasts (cardiovas-
cular, coagulation, hormones, inflammation and morphogen-
esis). The pathways forming the intrinsic group reflect canonical 
features of fibrotic fibroblasts5 with a dominant contribution by 
TGFβ. This dominance of TGFβ-related biology is apparent in 
the fibrosis node and in the contraction node, where activation 
of Rho GTPases can be triggered by TGFβ in a SMAD-indepen-
dent process,33 and in the activation node, where Ras, RAF1 and 
Figure 6 Potential mechanisms of interaction between IL-6 and TGFβ leading to fibrosis in SSc. (1) Inflammatory macrophage-produced IL-6 
enhances fibrogenic macrophage function (potential TCZ target). (2) IL-6 induces TGFβ production and enhances its signalling in fibroblasts (potential 
TCZ target). (3) TGFβ enhances IL-6 production by fibroblasts. (4) IL-6 directly activates fibroblasts to produce profibrotic proteins such as Col1 
(potential TCZ target). (5) TGFβ directly induces fibroblast differentiation into myofibroblasts. (6) Intracellularly, IL-6 classic signalling and TGFβ 
alternative signalling converge towards the activation of STAT3 (STAT3 → P-STAT3) resulting in aberrant expression of STAT3-dependent genes. 
αSMA, alpha-smooth muscle actin; Col1, collagen alpha 1; CTGF, connective tissue growth factor; ECM, extracellular matrix; GF, growth factor; 
IL-6, interleukin-6; JAK, Janus-activated kinase; JNK, Jun N-terminal kinase; P-STAT, phosphorylated STAT; STAT, signal transducer and activator of 
transcription; TGFβ, transforming growth factor beta; TGFβR, transforming growth factor beta receptor; TYK, tyrosine kinase.
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ERK are part of one branch of SMAD-independent TGFβ signal-
ling.34 Conversely, the pathways forming the extrinsic group 
represent biological processes that link inflammation and vascu-
lopathy to fibrosis. For example, not only are the cardiovascular 
pathways EDN1 and AGT potent mediators of vasoconstric-
tion,35 36 they are profibrotic mediators relevant to the patho-
biology of SSc.37 38 This is notable considering the prominent 
vasculopathy of SSc and the putative benefit for patients with 
SSc of drugs that target these pathways. Similarly, in addition 
to playing a key role in response to angiogenesis, vascular endo-
thelial growth factor A (VEGFA) and the VEGFA-inducing tran-
scription factor endothelial PAS domain-containing protein 1 
amplify fibrosis,39 creating a link between response to hypoxia 
and fibrosis. Although excessive inhibition of angiogenesis could 
be detrimental, our data support normalisation of the activation 
status of cardiovascular-related pathways rather than complete 
blockade of these pathways, which might be detrimental for 
wound healing or tissue repair.
Patient treatment with TCZ for 24 weeks profoundly affected 
the properties of explant dermal fibroblasts. It is not possible to 
determine whether treatment with TCZ modified the phenotype 
of resident cells or the cellular composition of the dermis; both 
these mechanisms are non-exclusive. Independent of the exact 
mechanism, the effect of IL-6Rα blockade on biological path-
ways dominated by TGFβ-related biology is striking and high-
lights the interaction between IL-6 and TGFβ. Although TGFβ 
is the quintessential profibrotic factor,9 IL-6 has also been shown 
to induce the production of fibrotic markers (CTGF, αSMA and 
collagen 1) by human fibroblasts in vitro.15 Hence, IL-6 and 
TGFβ may form a self-sustaining loop leading to fibrosis that 
could be interrupted by blockade of either or both cytokines. 
This is supported by recent work demonstrating that STAT3, the 
main downstream signalling element for IL-6, is an important 
TGFβ-dependent molecular checkpoint of fibrosis in SSc.40 Alto-
gether, these results and our observations at the whole-biopsy 
level21 suggest a potential interaction network between IL-6 and 
TGFβ involving fibroblasts and macrophages that leads to fibrosis 
in SSc (figure 6). Thus, blocking IL-6 signalling with TCZ may 
represent a novel approach to control both the TGFβ pathway 
and the inflammatory pathways, supporting further exploration 
of IL-6 and related mediators as potential therapeutic targets in 
SSc and other inflammation-driven fibrotic diseases.
A unique strength of this study is longitudinal sampling of 
well-characterised and otherwise untreated SSc patients with 
clinically active disease receiving TCZ or PBO treatment. The 
combination of clinical homogeneity of patients, repeat sampling 
at two time points and quality of characterisation assays allowed 
us to use relatively small numbers of samples to generate robust 
and reliable results. In addition, the combination of well-char-
acterised functional assays with gene expression analysis using 
RNA-Seq provides a rare window into the biology of active 
SSc. However, this study does not address the apparent discrep-
ancy between biological and clinical effects of TCZ on skin 
fibrosis. Although additional studies are needed to fill this gap, 
we hypothesise that TCZ primarily affects de novo fibrosis and 
has little impact on the reduction of established fibrosis. Hence, 
in established skin fibrosis, the clinical effect of TCZ would be 
substantially delayed after its biological effect.
In conclusion, this study in the field of SSc translational 
research sheds new light on SSc biology by leveraging the 
conduct of a well-designed clinical trial in SSc and rigorous func-
tional and molecular analysis of skin biopsy samples to eluci-
date the links between IL-6 biology and other key pathways and 
mediators in determining the hallmark profibrotic phenotype of 
SSc dermal fibroblasts. Moreover, our findings strongly support 
further exploration of IL-6 and related mediators as potential 
therapeutic targets in SSc and other fibrotic diseases.
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